A5067642403- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Glioma Diagnosis and Treatment
- Cancer Risks and Factors
- Cancer, Lipids, and Metabolism
- Brain Metastases and Treatment
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Cardiovascular Disease and Adiposity
- Peptidase Inhibition and Analysis
- Adipokines, Inflammation, and Metabolic Diseases
- Inflammatory mediators and NSAID effects
- Economic and Financial Impacts of Cancer
- Radiopharmaceutical Chemistry and Applications
- PI3K/AKT/mTOR signaling in cancer
- Cancer Cells and Metastasis
- CNS Lymphoma Diagnosis and Treatment
- Chemotherapy-induced cardiotoxicity and mitigation
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
Beaumont Hospital
2016-2025
Cancer Trials Ireland
2017-2024
Memorial Sloan Kettering Cancer Center
2011-2023
Cornell University
2011-2023
Royal College of Surgeons in Ireland
2017-2023
Imaging Center
2017-2023
Cold Spring Harbor Laboratory
2023
Cooper Medical School of Rowan University
2023
Botsford Hospital
2019-2020
Beaumont Hospital, Dearborn
2019-2020
A multicenter phase II study was conducted to assess the efficacy of rituximab, methotrexate, procarbazine, and vincristine (R-MPV) followed by consolidation reduced-dose whole-brain radiotherapy (rdWBRT) cytarabine in primary CNS lymphoma.Patients received induction chemotherapy with R-MPV (five seven cycles); those achieving a complete response (CR) rdWBRT (23.4 Gy), otherwise, standard WBRT offered (45 Gy). Consolidation given after radiotherapy. The end point 2-year progression-free...
Obesity is a risk factor for the development of hormone receptor-positive breast cancer in postmenopausal women and has been associated with an increased recurrence reduced survival. In humans, obesity causes subclinical inflammation visceral subcutaneous adipose tissue, characterized by necrotic adipocytes surrounded macrophages forming crown-like structures (CLS). Recently, we found numbers CLS, activation NF-κB transcription factor, elevated aromatase levels activity mammary glands obese...
Obesity and extracellular matrix (ECM) density are considered independent risk prognostic factors for breast cancer. Whether they functionally linked is uncertain. We investigated the hypothesis that obesity enhances local myofibroblast content in mammary adipose tissue these stromal changes increase malignant potential by enhancing interstitial ECM stiffness. Indeed, fat of both diet- genetically induced mouse models were enriched myofibroblasts stiffness-promoting components. These...
Abstract Obesity is a risk factor for hormone receptor-positive breast cancer in postmenopausal women. Estrogen synthesis catalyzed by aromatase, which encoded CYP19. We previously showed that aromatase expression and activity are increased the tissue of overweight obese women presence characteristic inflammatory foci [crown-like structures (CLS-B)]. In preclinical studies, proinflammatory prostaglandin E2 (PGE2) determinant expression. provide evidence cyclooxygenase (COX)-2–derived PGE2...
Abstract Purpose: Obesity, insulin resistance, and elevated levels of circulating proinflammatory mediators are associated with poorer prognosis in early-stage breast cancer. To investigate whether white adipose tissue (WAT) inflammation represents a potential unifying mechanism, we examined the relationship between WAT metabolic syndrome its prognostic importance. Experimental Design: was defined by presence dead/dying adipocytes surrounded macrophages forming crown-like structures (CLS)...
Purpose Although the accurate detection of osseous metastases in evaluation patients with suspected metastatic breast cancer (MBC) has significant prognostic and therapeutic implications, ideal diagnostic approach is uncertain. In this retrospective, single-institution study, we compare performance integrated positron emission tomography/computed tomography (PET/CT) bone scintigraphy (BSc) women MBC. Patients Methods Women MBC evaluated PET/CT BSc (within 30 days) between January 1, 2003...
There are no validated methods of early detection cardiotoxicity from trastuzumab (T) following anthracycline-based chemotherapy. Currently changes in left ventricular ejection fraction (LVEF) assessed but this approach has limited sensitivity and specificity. Within a prospective feasibility study dose-dense (dd) doxorubicin cyclophosphamide (AC) → weekly paclitaxel (P) with T lapatinib (L), we included preplanned analysis correlative cardiac Troponin I (cTnI) C-reactive protein (CRP) as...
Chronic inflammation is recognized as a risk factor for the development of several malignancies. Local white adipose tissue (WAT) inflammation, defined by presence dead or dying adipocytes encircled macrophages that form crown-like structures (CLS), occurs in breasts (CLS-B) most overweight and obese women. Previously, we showed CLS-B associated with elevated levels proinflammatory mediators aromatase, rate-limiting enzyme estrogen biosynthesis. The increased aromatase breast provide...
False negatives from nasopharyngeal swabs (NPS) using reverse transcriptase PCR (RT-PCR) in SARS-CoV-2 are high. Exhaled breath condensate (EBC) contains lower respiratory droplets that may improve detection. We performed EBC RT-PCR for genes (E, S, N, ORF1ab) on NPS-positive (n=16) and NPS-negative/clinically positive COVID-19 patients (n=15) two commercial assays. detected 93.5% (29/31) the four genes. Pre-SARS-CoV-2 era controls (n=14) were negative. was NPS negative/clinically 66.6%...
BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of or weight. This preplanned analysis the global randomized PALLAS trial investigates impact on side-effect profile, treatment adherence, efficacy palbociclib.
Abstract Background The current standard of care in the neoadjuvant setting for high-risk HER2-positive (HER2 +) breast cancer is to combine systemic chemotherapy with dual HER2 blockade, trastuzumab and pertuzumab. Targeted therapies have significantly improved outcomes patients cancer. To improve treatment-associated toxicity, chemotherapy-sparing approaches are currently being investigated. Trastuzumab deruxtecan (T-DXd) an HER2-directed antibody–drug-conjugate (ADC) promising results...
Purpose Metabolomics is a global study of metabolites in biological samples. In this we explored whether serum metabolomic spectra could distinguish between early and metastatic breast cancer patients predict disease relapse. Methods Serum samples were analysed from women with (n = 95) predominantly oestrogen receptor (ER) negative stage 80) using high resolution nuclear magnetic resonance spectroscopy. Multivariate statistics Random Forest classifier used to create prognostic model for...
Abstract BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer have a higher risk of locoregional recurrence (LRR), even in the setting early stage, lymph node‐negative disease. In this sequential, retrospective study, authors evaluated whether adjuvant trastuzumab was associated reduced LRR women node‐negative, HER2‐positive disease who received breast‐conservation therapy (BCT). METHODS: By using an institutional database, 197 were identified had...
Several large, randomized trials established the benefits of adjuvant trastuzumab with chemotherapy. However, benefit for women small, node-negative HER2-positive (HER2+) disease is unknown, as these patients were largely excluded from trials. Therefore, a retrospective, single-institution, sequential cohort study node-negative, HER2+ breast cancer who did or not receive was conducted.Women ≤ 2 cm, (immunohistochemistry 3+ fluorescence in situ hybridization ≥ 2) identified through an...
68Ga-1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-F(ab')2-trastuzumab [68Ga-DOTA-F(ab')2-trastuzumab] has been developed at our institution as a positron imaging reagent for assessing human epidermal growth factor receptor 2 (HER2) expression status by in-vivo imaging. Initial studies on animals demonstrated promising results in the monitoring of treatment response to heat shock protein 90-targeted drugs that inhibit client HER2. We report here initial clinical...
To determine whether the androgen receptor (AR) inhibitor, enzalutamide, improves effectiveness of endocrine therapy (ET) in hormone receptor-positive (HR+) breast cancer.In this phase II trial, patients with HR+/HER2 normal advanced/metastatic cancer were randomized 1:1 to exemestane 25 mg placebo or 50 enzalutamide 160 daily (NCT02007512). Two parallel cohorts enrolled 0 (cohort 1) 1 2) prior ET for advanced disease. Progression-free survival (PFS) was primary endpoint intent-to-treat...